http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=12789604&dopt=Abstract

Idrugs. 2003 May;6(5):486-90.
Borchmann P, Reiser M.
University of Cologne, First Department of Internal Medicine, Joseph-Stelzmann Strasse 9, 50924 Koeln, Germany

Novuspharma is developing pixantrone, a second-generation, well-tolerated anthracenedione analog, for the potential treatment of lymphoma and multiple sclerosis.